Accendra Health director granted 31,191 restricted shares

Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Beck Mark A reported acquisition or exercise transactions in this Form 4 filing.

Accendra Health Inc. director Mark A. Beck received a grant of 31,191 shares of common stock as equity compensation. The restricted stock was awarded at no cash cost to him and increases his direct holdings to 71,259 shares.

According to the terms, the restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting that is at least 50 weeks after the grant date. Until vesting, these shares are subject to forfeiture conditions typically linked to continued board service.

Insider Trade Summary

Grant/Award: 31,191 shares

Grant/Award 1 txn

Insider Beck Mark A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	31,191	$0.00	$0.00

Holdings After Transaction: Common Stock — 71,259 shares (Direct)

Footnotes (1)

1. F1. Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

Key Figures

Restricted stock grant: 31,191 shares Post-transaction holdings: 71,259 shares Grant price: $0.00 per share

3 metrics

Restricted stock grant 31,191 shares Common Stock awarded to director on May 14, 2026

Post-transaction holdings 71,259 shares Total common shares directly held after grant

Grant price $0.00 per share Reported transaction price for restricted stock award

Key Terms

Restricted stock grant, vests, annual meeting

3 terms

Restricted stock grant financial

"Restricted stock grant which vests the earlier of (i) one year from the grant date"

A restricted stock grant is an award of company shares given to an employee or executive that cannot be sold or transferred until certain conditions are met, such as staying with the company for a set time or hitting performance goals. For investors, it signals how the company ties pay to future performance and can affect the number of shares outstanding and management’s incentives—think of it as a wrapped gift you only keep once you meet the requirements.

vests financial

"Restricted stock grant which vests the earlier of (i) one year from the grant date"

annual meeting financial

"and (ii) the date of the next annual meeting that is at least 50 weeks"

A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Accendra Health (ACH) report for Mark A. Beck?

Accendra Health reported that director Mark A. Beck received a grant of 31,191 shares of common stock. This is a restricted stock award given as equity compensation, not an open-market purchase, and it increases his direct holdings to 71,259 shares.

Was the Accendra Health (ACH) stock grant to Mark A. Beck a purchase or a compensation award?

The transaction was a compensation award, classified as a grant or other acquisition, not a market purchase. The shares were issued at a stated price of $0.00 per share as restricted stock, reflecting typical director equity compensation rather than an investment-driven buy.

How many Accendra Health (ACH) shares does Mark A. Beck hold after this Form 4?

After receiving the restricted stock grant, Mark A. Beck directly holds 71,259 shares of Accendra Health common stock. This total includes the newly awarded 31,191 restricted shares, which are subject to vesting conditions tied to time and the company’s next annual meeting.

What are the vesting terms of Mark A. Beck’s restricted stock in Accendra Health (ACH)?

The restricted stock vests on the earlier of one year from the grant date or the date of the next annual meeting at least 50 weeks after the grant date. Until vesting, the shares remain restricted and can generally be forfeited if service conditions are not satisfied.

Does Accendra Health (ACH) Form 4 indicate any stock sales by Mark A. Beck?

This Form 4 does not report any stock sales by Mark A. Beck. It only shows an acquisition of 31,191 restricted common shares as a grant, with no open-market sale, disposition, or derivative exercise activity disclosed in the summarized data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 09:11 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beck Mark A

(Last) (First) (Middle)

ACCENDRA HEALTH, INC.

4435 WATERFRONT DRIVE

(Street)

GLEN ALLEN VIRGINIA 23060

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACCENDRA HEALTH INC/VA/ [ ACH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	05/14/2026		A		31,191	A	$0	71,259	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock grant which vests the earlier of (i) one year from the grant date and (ii) the date of the next annual meeting that is at least 50 weeks following the grant date.

	Mark A. Beck by Rosemarie France POA	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)